
CP 640186
CAS No. 591778-68-6
CP 640186 ( —— )
产品货号. M15192 CAS No. 591778-68-6
CP-640186 是一种同工酶非选择性乙酰辅酶A羧化酶 (ACCase) 抑制剂,对大鼠肝脏 ACC1 和大鼠骨骼肌 ACC2 的 IC50 值分别为 53 nM 和 61 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥786 | 有现货 |
![]() ![]() |
10MG | ¥1272 | 有现货 |
![]() ![]() |
25MG | ¥2082 | 有现货 |
![]() ![]() |
50MG | ¥2859 | 有现货 |
![]() ![]() |
100MG | ¥4261 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称CP 640186
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述CP-640186 是一种同工酶非选择性乙酰辅酶A羧化酶 (ACCase) 抑制剂,对大鼠肝脏 ACC1 和大鼠骨骼肌 ACC2 的 IC50 值分别为 53 nM 和 61 nM。
-
产品描述CP-640186 is an isozyme-nonselective Acetyl-CoA carboxylase (ACCase) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431.(In Vitro):CP-640186 (20 μM; 48 h) treatment can inhibit H460 cell growth.CP-640186 (0.1 nM-100 μM; 2 h) treatment increases fatty acid metabolism in a concentration-dependent manner in C2C12 cells and muscle strips.CP-640186 (0.62-1.8 μM; 2 h) treatment inhibits fatty acid synthesis and TG synthesis in HepG2 cells.(In Vivo):CP-640186 (oral gavage; 4.6-21 mg/kg; once) demonstrates acute efficacy.CP-640186 (intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once) shows lowe drug exposure in the rat than the ob/ob mouse at equal doses.CP-640186 (oral gavage; 100 mg/kg; once) treatment shows a complete shift from carbohydrate utilization to fatty acid utilization as a source of energy at high exposure level.
-
体外实验CP-640186 (20 μM; 48 h) treatment can inhibit H460 cell growth.CP-640186 (0.1 nM-100 μM; 2 h) treatment increases fatty acid metabolism in a concentration-dependent manner in C2C12 cells and muscle strips. CP-640186 (0.62-1.8 μM; 2 h) treatment inhibits fatty acid synthesis and TG synthesis in HepG2 cells.Cell Proliferation Assay Cell Line:Human fibroblasts and H460 cellsConcentration:20 μM Incubation Time:48 hours Result:Led to a ~30% decrease in cell number compared to vehicle-treated controls.Cell Viability Assay Cell Line:C2C12 cells and muscle strips Concentration:0.1 nM-100 μM Incubation Time:2 hours Result:Stimulated palmitate acid oxidation with an EC50 of 57 nM and a maximal stimulation of 280% in C2C12 cells.Stimulated palmitate acid oxidation with an EC50 of 1.3 μM and a maximal stimulation of 240% in isolated rat epitrochlearis muscle.Cell Viability Assay Cell Line:HepG2 cells Concentration:0.62-1.8 μM Incubation Time:6 hours Result:Inhibited fatty acid synthesis and TG synthesis in HepG2 cells with EC50s of 0.62 μM and 1.8 μM, respecticely.
-
体内实验CP-640186 (oral gavage; 4.6-21 mg/kg; once) demonstrates acute efficacy.CP-640186 (intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once) shows lowe drug exposure in the rat than the ob/ob mouse at equal doses. CP-640186 (oral gavage; 100 mg/kg; once) treatment shows a complete shift from carbohydrate utilization to fatty acid utilization as a source of energy at high exposure level. Animal Model:Male ob/ob miceDosage:4.6-21 mg/kg Administration:Oral gavage; 4.6-21 mg/kg; once Result:Demonstrated acute efficacy for up to 8 h after oral administration, exhibiting ED50 values of 4.6, 9.7, and 21 mg/kg, at 1, 4, and 8 h, respectively, after treatment.Animal Model:Male Sprague-Dawley rats Dosage:Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg Administration:Intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once Result:Showed a plasma half-life of 1.5 h, a bioavailability of 39%, a Clp of 65 ml/min/kg, a Vdss of 5 liters/kg, an oral Tmax of 1.0 h, an oral Cmax of 345 ng/mL, and an oral AUC0-∞ of 960 ng?h/mL.Animal Model:Male ob/ob mice Dosage:Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg Administration:Intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once Result:Showed a plasma half-life of 1.1 h, a bioavailability of 50%, a Clp of 54 ml/min/kg, an oral Tmax of 0.25 h, an oral Cmax of 2177 ng/mL, and an oral AUC0-∞ of 3068 ng?h/mL.Animal Model:Twenty male Sprague-Dawley rats (350-400 g) fasted and then refed a high sucrose diet for 2 days; additional eight rats fasted for 24 h Dosage:100 mg/kg Administration:Oral gavage; 100 mg/kg; once Result:Resulted in time-dependent reductions in RQ (a ratio of CO2 production to O2 consumption) of up to 64%.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点ACC
-
受体ACC
-
研究领域Metabolic Disease
-
适应症——
化学信息
-
CAS Number591778-68-6
-
分子量485.62
-
分子式C30H35N3O3
-
纯度>98% (HPLC)
-
溶解度DMSO: 10 mM
-
SMILESC1C[C@H](CN(C1)C2CCN(CC2)C(=O)C3=C4C=CC=CC4=CC5=CC=CC=C53)C(=O)N6CCOCC6
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Harwood HJ Jr, et al. J Biol Chem. 2003 Sep 26;278(39):37099-11
产品手册




关联产品
-
Tralkoxydim
Tralkoxydim 是一种烷基酮除草剂。 Tralkoxydim 用作 ACCase 抑制剂。
-
CP 640186
CP-640186 是一种同工酶非选择性乙酰辅酶A羧化酶 (ACCase) 抑制剂,对大鼠肝脏 ACC1 和大鼠骨骼肌 ACC2 的 IC50 值分别为 53 nM 和 61 nM。
-
PF-05175157
PF-05175157 (PF-5175157) 是一种有效的乙酰辅酶A羧化酶 (ACC) 抑制剂,对 hAAC1 和 hACC2 的 IC50 分别为 27 和 33 nM。